115 related articles for article (PubMed ID: 32115971)
1. MicroRNAs expression profiles as biomarkers and therapeutic tools in Turkish patients with chronic myeloid leukemia.
Yurt M; Ayyildiz O; Karakus A; Nursal AF; Isi H
Bratisl Lek Listy; 2020; 121(2):159-163. PubMed ID: 32115971
[TBL] [Abstract][Full Text] [Related]
2. Expression pattern of key microRNAs in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Fallah P; Amirizadeh N; Poopak B; Toogeh G; Arefian E; Kohram F; Hosseini Rad SM; Kohram M; Teimori Naghadeh H; Soleimani M
Int J Lab Hematol; 2015 Aug; 37(4):560-8. PubMed ID: 25833191
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth.
Agirre X; Jiménez-Velasco A; San José-Enériz E; Garate L; Bandrés E; Cordeu L; Aparicio O; Saez B; Navarro G; Vilas-Zornoza A; Pérez-Roger I; García-Foncillas J; Torres A; Heiniger A; Calasanz MJ; Fortes P; Román-Gómez J; Prósper F
Mol Cancer Res; 2008 Dec; 6(12):1830-40. PubMed ID: 19074828
[TBL] [Abstract][Full Text] [Related]
4. Down-regulation of miR-199b associated with imatinib drug resistance in 9q34.1 deleted BCR/ABL positive CML patients.
Joshi D; Chandrakala S; Korgaonkar S; Ghosh K; Vundinti BR
Gene; 2014 Jun; 542(2):109-12. PubMed ID: 24680705
[TBL] [Abstract][Full Text] [Related]
5. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia.
Xu C; Fu H; Gao L; Wang L; Wang W; Li J; Li Y; Dou L; Gao X; Luo X; Jing Y; Chim CS; Zheng X; Yu L
Oncogene; 2014 Jan; 33(1):44-54. PubMed ID: 23208504
[TBL] [Abstract][Full Text] [Related]
7. MicroRNAs that affect the Fanconi Anemia/BRCA pathway are downregulated in imatinib-resistant chronic myeloid leukemia patients without detectable BCR-ABL kinase domain mutations.
Yap E; Norziha ZA; Simbun A; Tumian NR; Cheong SK; Leong CF; Wong CL
Leuk Res; 2017 Aug; 59():32-40. PubMed ID: 28544907
[TBL] [Abstract][Full Text] [Related]
8. Restoration of miR-424 suppresses BCR-ABL activity and sensitizes CML cells to imatinib treatment.
Hershkovitz-Rokah O; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Raanani P; Shpilberg O; Granot G
Cancer Lett; 2015 May; 360(2):245-56. PubMed ID: 25697481
[TBL] [Abstract][Full Text] [Related]
9. microRNA expression profiling as supportive diagnostic and therapy prediction tool in chronic myeloid leukemia.
Jurkovicova D; Lukackova R; Magyerkova M; Kulcsar L; Krivjanska M; Krivjansky V; Chovanec M
Neoplasma; 2015; 62(6):949-58. PubMed ID: 26458312
[TBL] [Abstract][Full Text] [Related]
10. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells.
Rokah OH; Granot G; Ovcharenko A; Modai S; Pasmanik-Chor M; Toren A; Shomron N; Shpilberg O
PLoS One; 2012; 7(4):e35501. PubMed ID: 22511990
[TBL] [Abstract][Full Text] [Related]
11. [Genetic diagnosis of chronic myeloid leukemia].
Kato C; Naoe T
Nihon Rinsho; 2001 Dec; 59(12):2336-41. PubMed ID: 11766335
[TBL] [Abstract][Full Text] [Related]
12. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
Drexler HG; MacLeod RA; Uphoff CC
Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
14. Dysregulation of miRNA expression in patients with chronic myelogenous leukemia at diagnosis: a systematic review.
Parsa-Kondelaji M; Musavi M; Barzegar F; Abbasian N; Rostami M; R Seyedtaghia M; S Hashemi S; Modi M; Nikfar B; A Momtazi-Borojeni A
Biomark Med; 2023 Dec; 17(24):1021-1029. PubMed ID: 38230979
[No Abstract] [Full Text] [Related]
15. miR-96 acts as a tumor suppressor via targeting the BCR-ABL1 oncogene in chronic myeloid leukemia blastic transformation.
Huang T; Fu Y; Wang S; Xu M; Yin X; Zhou M; Wang X; Chen C
Biomed Pharmacother; 2019 Nov; 119():109413. PubMed ID: 31518872
[TBL] [Abstract][Full Text] [Related]
16. microRNA-21 Expression as Prognostic and Therapeutic Response Marker in Chronic Myeloid Leukaemia Patients.
Mirza MAB; Guru SA; Abdullah SM; Rizvi A; Saxena A
Asian Pac J Cancer Prev; 2019 Aug; 20(8):2379-2383. PubMed ID: 31450909
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-451 in chronic myeloid leukemia: miR-451-BCR-ABL regulatory loop?
Lopotová T; Záčková M; Klamová H; Moravcová J
Leuk Res; 2011 Jul; 35(7):974-7. PubMed ID: 21511335
[TBL] [Abstract][Full Text] [Related]
18. [A clinical and laboratory study of chronic myeloid leukemia with atypical BCR-ABL fusion gene subtypes].
Gui X; Pan J; Qiu H; Cen J; Xue Y; Chen S; Shen H; Yao L; Zhang J; Wu Y; Chen Y
Zhonghua Xue Ye Xue Za Zhi; 2014 Mar; 35(3):210-4. PubMed ID: 24666486
[TBL] [Abstract][Full Text] [Related]
19. [Detection of phosphotyrosine in chronic myeloid leukemia cells with PY20 antibody and its clinical applications].
Tian J; Cheng H; Xu KL; Pan XY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):1056-60. PubMed ID: 19698259
[TBL] [Abstract][Full Text] [Related]
20. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
Ali MA
Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
